Kura Oncology (NASDAQ:KURA) Receives Outperform Rating from Wedbush

Wedbush reissued their outperform rating on shares of Kura Oncology (NASDAQ:KURA - Free Report) in a report published on Friday morning,Benzinga reports. The brokerage currently has a $36.00 price objective on the stock.

A number of other equities research analysts have also recently issued reports on KURA. UBS Group dropped their price target on shares of Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. Barclays reduced their price target on Kura Oncology from $32.00 to $11.00 and set an "overweight" rating on the stock in a report on Friday, May 2nd. Mizuho reduced their price objective on shares of Kura Oncology from $32.00 to $30.00 and set an "outperform" rating on the stock in a report on Monday, May 19th. JMP Securities reaffirmed a "market outperform" rating and issued a $28.00 target price on shares of Kura Oncology in a research report on Wednesday, June 4th. Finally, Wall Street Zen downgraded Kura Oncology from a "buy" rating to a "hold" rating in a research report on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $24.50.

Kura Oncology Stock Up 0.3%

Shares of KURA stock traded up $0.02 during mid-day trading on Friday, hitting $5.87. 999,696 shares of the stock traded hands, compared to its average volume of 1,236,105. The stock has a market cap of $508.17 million, a P/E ratio of -2.80 and a beta of 0.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.07 and a quick ratio of 8.07. The stock's fifty day moving average is $6.18 and its two-hundred day moving average is $7.26. Kura Oncology has a 52-week low of $5.41 and a 52-week high of $23.48.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The company had revenue of $14.11 million for the quarter, compared to analysts' expectations of $39.08 million. Equities analysts predict that Kura Oncology will post -2.44 EPS for the current year.

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KURA. State of Wyoming acquired a new stake in Kura Oncology during the 1st quarter worth $48,000. Virtus ETF Advisers LLC lifted its stake in shares of Kura Oncology by 71.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock valued at $64,000 after purchasing an additional 3,061 shares during the period. Pallas Capital Advisors LLC purchased a new position in Kura Oncology during the 1st quarter valued at about $66,000. Flower City Capital purchased a new position in Kura Oncology during the 1st quarter valued at about $79,000. Finally, Magnetar Financial LLC purchased a new position in Kura Oncology during the 1st quarter valued at about $79,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.